Press Release – CounterX Therapeutics

March 2, 2026 in Press Release

CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders

PRESS RELEASE CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders SEATTLE, WA – (February 26, 2026) CounterX Therapeutic ...

October 29, 2025 in Press Release

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

pjwcreative 1 Like Post Comments Off

PRESS RELEASE CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model SEA ...

CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

An anti-fentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs

Psychopharmacology: A humanized monoclonal antibody attenuates fentanyl self-administration and reverses and prevents fentanyl-induced ventilatory depression in rhesus monkeys

ACS Omega: Structure-Based Engineering of Monoclonal Antibodies for Improved Binding to Counteract the Effects of Fentanyl and Carfentanil

The Journal of Immunology: Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity

CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model